The Latest Breaking News from Eczema

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Sanofi stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent.

Evidence suggests that early exposure to family members, food, germs, dust, dirt, pollen, and pets shapes our immune response

As the number of people with allergies grows worldwide, scientists are trying to work out precisely how and why these conditions – such as asthma and eczema – develop.

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot to control eczema.

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

Nektar Therapeutics stock launched Tuesday after the biotech company hit every goal in a midstage study of its eczema treatment.

IN FULL

Academics said that having a pet dog in early life could have a ‘protective effect’